Nifedipine Pharmacokinetics Are Influenced byCYP3A5Genotype When Used as a Preterm Labor Tocolytic

    loading  Checking for direct PDF access through Ovid

Abstract

Objective

To characterize the pharmacokinetics and pharmacogenetics of nifedipine in pregnancy.

Study Design

Pregnant women receiving oral nifedipine underwent steady-state pharmacokinetic testing over one dosing interval. DNA was obtained and genotyped for cytochrome P450 (CYP) 3A5 and CYP3A4*1B. Nifedipine and oxidized nifedipine concentrations were measured in plasma, and pharmacokinetic parameters were compared between those women who expressed a CYP3A5*1 allele and those who expressed only variant CYP3A5 alleles (*3,*6, or *7).

Results

Fourteen women had complete data to analyze. Four women (29%) expressed variant CYP3A5; three of these women were also CYP3A4*1B allele carriers. The mean half-life of nifedipine was 1.68 ± 1.56 hours. The area under the curve from 0 to 6 hours for the women receiving nifedipine every 6 hours was 207 ± 138 μg·h /L. Oral clearance was different between high expressers and low expressers (232.0 ± 37.8 μg/mL versus 85.6 ± 45.0 μg/mL, respectively; p = 0.007).

Conclusion

CYP3A5 genotype influences the oral clearance of nifedipine in pregnant women.

Related Topics

    loading  Loading Related Articles